Title |
BAD: a good therapeutic target?
|
---|---|
Published in |
Breast Cancer Research, December 2002
|
DOI | 10.1186/bcr552 |
Pubmed ID | |
Authors |
Andrea B Motoyama, Nancy E Hynes |
Abstract |
The major goal in cancer treatment is the eradication of tumor cells. Under stress conditions, normal cells undergo apoptosis; this property is fortunately conserved in some tumor cells, leading to their death as a result of chemotherapeutic and/or radiation-induced stress. Many malignant cells, however, have developed ways to subvert apoptosis, a characteristic that constitutes a major clinical problem. Gilmore et al. recently described the ability of ZD1839, a small-molecule inhibitor of the epidermal growth factor receptor (EGFR), to induce apoptosis of mammary cells that are dependent upon growth factors for survival. Furthermore, they showed that the major effector of the EGFR-targeted therapy is BAD, a widely expressed BCL-2 family member. These results are promising in light of the role of the EGFR in breast cancer development. |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Germany | 1 | 20% |
Unknown | 4 | 80% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Researcher | 2 | 40% |
Student > Ph. D. Student | 2 | 40% |
Professor | 1 | 20% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 3 | 60% |
Agricultural and Biological Sciences | 1 | 20% |
Biochemistry, Genetics and Molecular Biology | 1 | 20% |